The FDA has approved the use of nivolumab in combination with chemotherapy for the treatment of certain patients with resectable non–small cell lung cancer. Specifically, the drug can be used as neoadjuvant treatment followed by adjuvant monotherapy after surgery in adults with stage IIA-IIIB disease. The approval was based on positive findings from the CheckMate 77T trial, which showed an event-free survival benefit with nivolumab compared to placebo. Safety was comparable to other trials with 5.3% of patients in the nivolumab group unable to undergo surgery. The recommended dosage and administration schedule have been outlined by the FDA.
Source link
Nivolumab NSCLC Approval Expanded to Perioperative Setting
